Prolacta Bioscience, a US-based hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced on Tuesday that it has named David Steinberg as its new chief financial officer.

In the new role, Steinberg will be responsible for managing the company's financial operations, including financial planning, reporting, accounting, business development, and investor relations.

Steinberg has around three decades of experience in biopharmaceutical equity research. He has held the position of managing director for Jefferies and Deutsche Bank. He has experience in capital fundraising and has been instrumental in introducing over 50 successful pharma and biotech initial public offerings (IPOs), and he has been involved in supporting entrepreneurial biopharmaceutical companies in raising over USD25bn in equity and equity-linked securities.